Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia

Pedro Monteiro a,b, Ana I. Duarte c, Lino M. Gonçalves b,c,∗, António Moreno c, Luís A. Providência b,c

a Basic Research Unit in Cardiology, Cardiology Department, Coimbra University Hospital, Coimbra, Portugal
b Coimbra University, Medical School, Portugal
c Centre for Neuroscience and Cell Biology of Coimbra, Portugal

Received 11 June 2004; received in revised form 26 August 2004; accepted 1 September 2004
Available online 5 October 2004

Abstract

Trimetazidine is an anti-ischemic drug whose cytoprotective mechanisms are not yet fully understood (but until now mainly related to the trimetazidine-induced “metabolic shift” from lipid β-oxidation to glucose aerobic oxidation). We studied the effect of trimetazidine on the mitochondrial function of ischemic Wistar rat hearts perfused with glucose, using a model of ex-vivo perfusion (Langendorff system). We measured the electrical potential of the mitochondrial membrane, O2 consumption by the respiratory chain, energy charges generated and the enzyme activities of the respiratory chain complexes. In this model, trimetazidine had a preferential action on the oxidative system (mainly on complex I), increasing its enzyme activity and decreasing O2 consumption after phosphorylation; this could decrease oxygen free radical production and increase mitochondrial integrity, thus allowing the maintenance of the electrical potential. These results allow us to better understand the cytoprotective effects of trimetazidine in coronary artery disease.

© 2004 Elsevier B.V. All rights reserved.

Keywords: Ischemia; Mitochondrion; Trimetazidine; Perfusion; Glucose

1. Introduction

Trimetazidine (1-[2, 3 4-trimethoxybenzyl]-piperazine dihydrochloride), was first used to treat angina in 1964. Trimetazidine is a known metabolic anti-ischemic agent with no significant hemodynamic effects. Clinically, trimetazidine decreases ischemia during coronary angioplasty (Kober et al., 1992) and cardiac surgery (Fabiani et al., 1992) and there is clear evidence that it can improve exercise tolerance in patients with coronary artery disease (Sellier et al., 1987), showing a similar efficacy to propranolol (Detry et al., 1994) or nifedipine (Dalla-Volta et al., 1990). Despite these clinical benefits, the mechanisms involved in its protective effects are not completely understood.

The major source of energy for the cardiac myocyte during aerobic conditions is fatty acid oxidation (Stanley et al., 1997). However, during ischemia the lack of oxygen partially shifts metabolism from fatty acid to glucose oxidation (Veitch et al., 1995). At least part of the protective effects of trimetazidine during ischemia can be explained by enhancement of the “metabolic shift”, from lipid oxidation to glucose oxidation (Sentex et al., 1998). This metabolic shift can be explained by an increase in pyruvate dehydrogenase activity (Stanley et al., 1997; Kantor et al., 2000) and by the inhibition of 3-ketoacetyl coenzyme A thiolase (3-KAT) (Kantor et al., 2000).

In hearts not submitted to ischemia, trimetazidine induces a decrease in complex I-mediated O2 consumption during
state 3 of mitochondrial respiration, which has been interpreted as possible evidence of a specific inhibition of complex I in non-ischemic mitochondria (Stanley et al., 1997). However, this effect was only observed using high concentrations of trimetazidine (≥100 μM) and was not confirmed by other authors using ex-vivo animal models (Kantor et al., 2000).

Using a model of hypoxia–reoxygenation, Fantini and coworkers have demonstrated that isolated myocytes treated with trimetazidine release less lactate dehydrogenase (LDH), even when exposed to oxidant agents (like oxygen peroxide—H₂O₂). In this experimental model, trimetazidine did not change ATP production, either during hypoxia or reoxygenation. This effect of trimetazidine was attributed by the authors not to its antioxidant properties, but to changes in lipid metabolism (Fantini et al., 1994). In other models of ischemia–reperfusion, it has been demonstrated that the impact of ischemia on the mitochondrial respiratory chain mainly occurs at the level of complex I (Veitch et al., 1992).

In ischemic models, a decrease in intracellular acidosis can be expected, providing that trimetazidine is present in the perfusion media (Renaud, 1988). This raises the hypothesis that trimetazidine acts on heart mitochondria, thus allowing a better use of the limited amount of O₂ available during ischemia, by mechanisms not yet fully understood, but which may involve a preferential use of glucose and/or a decrease in reactive oxygen species production (Maupoil et al., 1990). In ischemic hearts perfused with free fatty acids and trimetazidine, ATP levels have been shown to be preserved by some authors (Fantini et al., 1994) and decreased by others (Demaison et al., 1995).

Most of the knowledge gathered so far about the intracellular mechanisms of trimetazidine was obtained from animal models perfused with lipids. Because ischemia is associated with a metabolic “shift” from fatty acid oxidation to glucose oxidation, and since this metabolic “shift” is further enhanced by treatment with trimetazidine (Kantor et al., 2000), we decided to determine the influence of trimetazidine on the mitochondrial function of ischemic rat hearts perfused with glucose (without the confounding effect of lipids). We demonstrate that trimetazidine improves, in a specific way, mitochondrial complex I enzyme activity, resulting in a more efficient consumption of O₂ together with a better preservation of the mitochondrial transmembrane electrochemical gradient. This increase in complex I enzyme activity may further explain the cardioprotective effect of trimetazidine beyond the reported “metabolic shift”.

2. Materials and methods

This investigation conformed with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health—NIH publication No. 85-23, revised 1996 (National Research Council, 1996) and it was approved by the Ethics Committee of the Centre for Neuroscience and Cell Biology of Coimbra, where the experimental work took place. All compounds were the purest quality available and were ordered from Sigma (St. Louis, MO) or Merck (Darmstadt, Germany), except for trimetazidine, which was obtained from Servier (Courbevoie, France).

2.1. Experimental groups

Thirty female Wistar rats were randomly distributed over three experimental groups: control (n=10), ischemia (n=10) and ischemia + trimetazidine 25 μM (n=10).

2.2. Assembly of the ex-vivo perfusion system

Wistar rats, weighing around 300 g, were killed by CO₂ inhalation. Each heart was rapidly excised and mounted in a Langendorff perfusion apparatus (model UP-100 from Hugo Sachs Elektronik, Germany), and then perfused at a constant flow (25 mL/min) with a Krebs modified solution (NaCl 118 mM, KCl 4.7 mM, KH₂PO₄ 1.2 mM, NaHCO₃ 25 mM, MgSO₄ 1.2 mM, Na₂EDTA 0.5 mM, Glucose 10 mM and CaCl₂ 3 mM; pH 7.4), gassed with carbogen (95%O₂–5%CO₂). Temperature was continuously monitored and maintained at 37 °C (via a thermostatic bath) throughout the perfusion period (180 min for the control group and 60 min for the remaining groups); pH was also continuously monitored with a pH electrode and kept stable at 7.35–7.45 during this period. Trimetazidine (25 μM) was added to the Krebs modified solution in the respective experimental group. Left ventricular pressure and heart rate were recorded at regular intervals.

After the initial perfusion, all rat hearts, with the exception of the control group, were submitted to 120 min of ischemia at 37 °C in a solution identical to that of the perfusion period, but without glucose and carbogen (replaced by nitrogen).

2.3. Preparation of the biological material

2.3.1. Isolation of rat heart mitochondria

At the end of the perfusion and ischemia periods, the mitochondrial fraction from each rat heart was prepared according to the method described by Rickwood et al. (1987). All the parameters of mitochondrial function were assessed in the isolated mitochondrial fraction.

2.4. Laboratory methods used

The laboratory methods used in this experimental protocol have been described earlier (Monteiro et al., 2003).

2.4.1. Statistical analysis

Results are presented as means±standard error (raw data or expressed as percentage of control), for the number of
results indicated. Results were analyzed using the Student t-test. The level of significance used was P<0.05.

3. Results

Oxidative phosphorylation is very sensitive to ischemia, which affects mitochondrial coupling, as demonstrated by the decrease in the respiratory rate when compared with mitochondria of the control group (2.68±0.25 versus 1.51±0.13; P=0.0002). Trimetazidine (25 μM) significantly protected heart mitochondria from the deleterious effects of ischemia on mitochondrial respiration (using glutamate/malate as energy substrate). This decrease resulted in a higher respiratory control ratio in this experimental group (2.71±0.42—Fig. 2), significantly higher than that in the ischemic group (P=0.0002) and similar to that of the control group (P=n.s.).

When glutamate/malate was used as energy substrate, the electrical potential (ΔΨ) decreased in a significant manner during ischemia, compared to that in the control group (209.13±1.37 versus 186.66±3.36 mV; P=0.000001). The same occurred when succinate (211.32±3.24 versus 187.23±4.74 mV; P<0.05) and ascorbate/TMPD (N,N,N′,N′-Tetramethyl-P-phenylenediamine) (209.09±2.53 versus 189.24±3.98 mV; P<0.05) were used. In mitochondria from trimetazidine-treated hearts, ΔΨ increased significantly to 199.49±1.7 mV (P=0.004) (Fig. 3A). Similar results were obtained when succinate (197.41±1.84 versus 187.23±4.74 mV; P=0.04) and ascorbate/TMPD (199.77±1.21 versus 189.24±3.98 mV; P=0.01) were used as energy substrates (Fig. 3A).

Another parameter evaluated was the amount of time needed to phosphorylate a fixed amount of ADP (250 nmol)—the so-called lag phase. The lower this value is, the quicker the phosphorylation cycle is completed. The lag phase was increased in mitochondria from hearts of the ischemic group, when compared to those from the control group, not only with glutamate/malate (59.08±6.82 versus 127.2±19.03 s; P=0.001), but also with succinate (66.46±6.43 versus 275.73±45.99 s; P=0.0001) and ascorbate/TMPD (31.5±2.11 versus 62.4±11.63 s; P=0.001).

Compared to the ischemic group (Fig. 3B), mitochondria from hearts treated with trimetazidine 25 μM had a similar lag phase, independent of the energy substrate used: glutamate/malate (132.1±21.39 versus 127.2±19.03 s; P=n.s.), succinate (250.62±17.05 versus 275.73±45.99 s; P=n.s.) or ascorbate/TMPD (48.3±6.39 versus 62.4±11.63 s; P=n.s.).

We also determined the energy charge ([ATP]+0.5*[ADP]/([ATP]+[ADP]+[AMP])) obtained when using glutamate/malate, succinate and ascorbate/TMPD. As for other parameters, the mitochondria from the ischemic group generated a lower energy charge per phosphorylation cycle, when compared to those of the control group, independent of the energy substrate used. The difference between the two groups reached statistical significance with glutamate/malate (0.965±0.005 versus 0.94±0.01; P<0.04), but not with succinate (0.79±0.051 versus 0.64±0.04; P=n.s.) and ascorbate/TMPD (0.7±0.04 versus 0.59±0.03; P=n.s.). The energy charge of mitochondria from the trimetazidine-treated group, was similar (P=n.s.) to that of the ischemic hearts not treated with trimetazidine (Fig. 3C), regardless of the energy substrate used (glutamate/malate: 0.91±0.04; succinate: 0.65±0.09; ascorbate/TMPD: 0.59±0.12).

Finally, we evaluated the enzyme activity of complexes I, II–III and IV. A statistically significant difference (P<0.05) between mitochondria from ischemic and control hearts, was observed for all four enzyme complexes evaluated (complex I: 100% versus 63.23±5.18%; complexes II–III: 14370±1174 versus 8592±663 nmol succinate oxidized/min/mg protein; complex IV: 853±66 versus 608±58 nmol O2 consumed/min/mg protein; ATP synthase: 795±75 versus 426±35 nmol H+ released/min/mg protein).

Mitochondria from hearts submitted to ischemia in the presence of trimetazidine showed a significant increase in the complex I enzyme activity, when compared with both those from the ischemic group (153.85±10.58% versus 63.23±5.18%; P=0.0001) and the control group (153.85±10.58% versus 100%; P=0.02). Trimetazidine induced a non-statistically significant increase in the enzyme activity of complexes II–III, when compared with mitochondria from ischemic hearts not treated with trimetazidine (9357±593 versus 8592±663 nmol succinate oxidized/min/mg protein; P=n.s.). Complex IV (606±40 versus 608±58 nmol O2 consumed/min/mg protein) and ATP synthase (432±83

Fig. 1. Typical recording of O2 consumption during states 3 and 4 of mitochondrial respiration (using glutamate/malate as energy substrate).

Fig. 2. Comparison of respiratory control ratio in rat heart mitochondria (control, ischemic and trimetazidine groups) with glutamate/malate as energy substrate. *P<0.05 versus ischemic group; values are expressed in arbitrary units.
versus 426±35 nmol H⁺ released/min/mg protein) enzyme activities were similar (P=n.s.) in mitochondria from the trimetazidine and ischemic groups (Fig. 4A, B, C and D).

4. Discussion

Since it has been shown that during ischemia there is an increased use of glucose as the myocardial energy source, when studying the impact of a drug on cardiac mitochondrial metabolism during ischemia it is important to perfuse the hearts with glucose. Furthermore, because we wanted to investigate the impact of trimetazidine on cardiomyocyte function beyond the already proven "metabolic shift", it was imperative not to use lipids as the energy substrate.

Trimetazidine (25 μM) had a global positive effect, but this effect was of different magnitude when considering the phosphorylation and oxidation systems. Trimetazidine had little effect on the phosphorylation system (energy charge, lag phase and ATP synthase enzyme activity). These results are in accordance with those of other investigators, who showed that trimetazidine was unable to improve the mitochondrial energy charge in animal models of myocardial ischemia (Fantini et al., 1994; Hugtenburg et al., 1989). During ischemia, trimetazidine was able to significantly improve variables related to the status of the mitochondrial respiratory chain. There was a significant increase in the respiratory control rate and, mainly, an increase in complex I enzyme activity. In similar experimental models, but in which a perfusion medium without glucose (replaced by fatty acids) was used, trimetazidine had a negative impact on the respiratory control rate (Fantini et al., 1994). These different results could be explained by the preferential use, by ischemic hearts, of glucose as energy substrate (instead of fatty acids). This preferential use of glucose is increased in the presence of trimetazidine.

A more detailed analysis of components of respiratory control ratio (O₂ consumption in states 3 and 4 of
mitochondrial respiration) showed that the protective effect of trimetazidine under these experimental conditions seemed to be mainly due to a more efficient use of O₂ during state 4 of mitochondrial respiration. Other authors have demonstrated, in similar animal models, different results using fatty acids as substrate. Fantini et al. (1994) observed a decrease in O₂ consumption during state 3. The explanation for these differences could be related to the different substrates used and to the fact that ischemic hearts prefer to use glucose as substrate (situation improved by trimetazidine itself).

The effect of trimetazidine on mitochondrial respiration observed in our experimental model could be explained by an increase in the activity of complex I during ischemia (with a consequent decrease in the production of reactive oxygen species). This enzyme-based mechanism could explain the antioxidant properties of trimetazidine already described by Maupoil et al. (1990). The confirmation of our findings in future studies may make it possible to explain the molecular mechanisms involved in that antioxidant effect (until now mainly regarded as a mere consequence of the trimetazidine-induced “metabolic shift”) (Kantor et al., 2000) and to fully explain the anti-ischemic effect of trimetazidine, as these new data clearly demonstrate that it goes far beyond the “metabolic shift” (being also present in an experimental model in which the hearts were not exposed to free fatty acids).

The decrease in reactive oxygen species production could also explain the higher membrane electrical potential found in the mitochondria from hearts treated with trimetazidine. It was previously demonstrated that reactive oxygen species are responsible for peroxidation, which compromises membrane integrity (Maridonneau-Parini and Harpey, 1985) and, consequently, the maintenance of normal electrochemical gradients. In fact, Fantini et al. (1994) have already suggested that trimetazidine preserves membrane integrity. This effect could be determined by the direct antioxidant effect, by a membrane-stabilizing effect unrelated to antioxidant mechanisms or by a decrease in cellular activity (in metabolic and/or mechanical terms), supposedly related to the negative chronotropic and inotropic effects of trimetazidine (Lavanchy et al., 1987).

5. Conclusions

By promoting the activity of the mitochondrial respiratory chain complex I in ischemic cardiomyocytes, trimetazidine enables a more efficient O₂ consumption during the metabolism of glucose. This action could lead to a decrease in reactive oxygen species production and to an increase in mitochondrial membrane integrity, resulting in a better preservation of the transmembrane electrochemical gradient. All these effects have a positive impact on mitochondrial homeostasis and, therefore, on the metabolism of cardiomyocytes during ischemia.

It is clearly demonstrated that, during acute ischemia, the positive effects of trimetazidine are not primarily due to an increase in ATP production, but to an impact on the mitochondrial respiratory chain, increasing complex I activity and thus decreasing futile O₂ consumption and reactive oxygen species production.
Acknowledgement

This study was supported by grants from the Portuguese Society of Cardiology and the Procardio.

References


